Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab
Barrientos J, Wagner-Johnston ND, De Vos S, et al.
Key Points:
Investigators present data from phase 1 study of idelalisib (IDELA) in combination with two chemo-immunotherapy regimens: bendamustine/rituximab (IDELA+BR) and chlorambucil/rituximab (IDELA+ChR)
Median exposure was IDELA+BR: 18.4 months (Min, Max: 1.2, 24.7) and IDELA+ChR: 7.7 months (Min, Max: 1.9, 11.1)
Common AEs (both groups): pyrexia, diarrhea, fatigue, neutropenia, thrombocytopenia, transaminase elevations, anemia
Objective response rates (ORR): 89.7% (95% CI (%): 72.6-97.8)
Median time to response: 1.9 months
IDELA+BR: ORR: 86.7%; CR: 6.7%; PR: 80%; median DOR/PFS: not reached, median exposure:18.4 months
IDELA+ChR: ORR: 92.9%, CR: 14.3%, PR: 78.6%, median DOR/PFS: not reached, median exposure: 7.7 months.
Implications:
- Combination of IDELA+BR or IDELA+ChR tolerable and efficacious option in this particularly difficult-to-treat CLL patient population with refractory disease.
View the original abstract on the ASH website.
